Ionis Pharmaceuticals lowered its full-year 2026 sales guidance for its drug TRYNGOLZA from $100-$110 million to about $50 million, citing slower-than-expected market adoption. The drug had generated $32 million in sales in the first half of 2026 but is now expected to see a more gradual launch. This downgrade caused Ionis' stock price to fall sharply. Investors who suffered losses are being encouraged to submit information for a potential securities law investigation into whether the company made misleading statements about TRYNGOLZA's sales prospects.
Ionis Pharmaceuticals' stock price dropped sharply by 21.36% on Pluang as of Nov 10, 2026 05:21 WIB, trading at USD 31.00. This decline contrasts with the typical hold time of 10 days on the platform, indicating a swift reaction from investors. Despite the sell-off, all current Pluang orders remain buy orders, showing continued interest in the stock even after the downgrade.
Ionis Pharmaceuticals cut its 2026 sales forecast for TRYNGOLZA from $100-110 million to about $50 million due to a slower-than-expected commercial launch. This significant downgrade raised concerns about whether the company had previously disclosed ...
Ionis Pharmaceuticals sharply reduced its revenue guidance for one of its main drugs due to weak sales, causing its stock to fall significantly in premarket trading. This revenue cut overshadows the company's otherwise solid earnings report. The lowe...
